CN102210676A - Antibacterial composite medicine containing sulbenicillin sodium and clavulanic acid compound - Google Patents
Antibacterial composite medicine containing sulbenicillin sodium and clavulanic acid compound Download PDFInfo
- Publication number
- CN102210676A CN102210676A CN2011101144105A CN201110114410A CN102210676A CN 102210676 A CN102210676 A CN 102210676A CN 2011101144105 A CN2011101144105 A CN 2011101144105A CN 201110114410 A CN201110114410 A CN 201110114410A CN 102210676 A CN102210676 A CN 102210676A
- Authority
- CN
- China
- Prior art keywords
- clavulanic acid
- antibacterial
- sulbenicillin disodium
- sulbenicillin
- antibacterial compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides an antibacterial composite medicine containing sulbenicillin sodium and a clavulanic acid compound, a freeze-dried powder injection containing the antibacterial medicinal composition. The medicine consists of sulbenicillin sodium and a clavulanic acid compound, which are in a weight ratio of (2-7):1. Under the same antibacterial condition, the antibacterial composite medicine provided by the invention reduces medicine dose, economic load of patients and production cost.
Description
Technical field
The present invention relates to antibacterial compound drug, particularly, relate to a kind of antibacterial compound drug and lyophilized injectable powder thereof that contains sulbenicillin disodium.
Background technology
In recent years, sulbenicillin disodium has obtained using widely as antibiotic clinically.But along with using widely, antibacterial strengthens the drug resistance of sulbenicillin disodium, increases the also very difficult bactericidal effect that reaches again once of using dosage.Heavy dose of use sulbenicillin disodium has not only increased patient's financial burden, also can further strengthen the Drug resistance of antibacterial.In order to solve the drug resistance that improves day by day, demand developing a kind of new antibacterial compound drug urgently.
Summary of the invention
The object of the present invention is to provide a kind of antibacterial compound drug that contains sulbenicillin disodium and clavulanic acid compounds, this antibacterial compound drug consumption is few, has a broad antifungal spectrum and bactericidal effect are good.
The antibacterial compound drug that contains sulbenicillin disodium and clavulanic acid compounds provided by the invention is made up of sulbenicillin disodium and clavulanic acid compounds, and wherein sulbenicillin disodium and clavulanic acid compounds weight ratio are 2～7: 1.In another embodiment, the clavulanic acid compounds is a clavulanate potassium.
In another embodiment, sulbenicillin disodium and clavulanic acid compounds weight ratio are 3: 1; Preferably, this ratio can be 4: 1.
The present invention also provides a kind of lyophilized injectable powder, and the effective ingredient of this lyophilized injectable powder is above-mentioned arbitrary antibacterial compound drug.
Further, lyophilized injectable powder administering mode provided by the invention is: with sulbenicillin disodium and clavulanic acid compounds by 2～7: 1 weight ratio is made lyophilized injectable powder after mixing; Perhaps with sulbenicillin disodium and clavulanic acid compounds respectively as its effective ingredient, and mix the back administration by aforementioned weight ratio after making lyophilized injectable powder; After perhaps sulbenicillin disodium and clavulanic acid compounds being made lyophilized injectable powder respectively, by the administration respectively of aforementioned weight ratio.
The technology of the present invention effect:
Also contain the clavulanic acid compounds in the antibacterial compound drug that contains sulbenicillin disodium provided by the invention,, under the prerequisite of same sterilization effects, reduced the consumption of sulbenicillin disodium by the synergism of these two kinds of medicines.
Another effect of the present invention is that under the prerequisite that does not lessen the curative effect, amount of drug significantly reduces, and has alleviated patient's financial burden.
The specific embodiment
Sulbenicillin disodium has another name called Sulbenicillin, is white or pale yellow powder, and is very easily water-soluble.This medicine synthesizes by the inhibition bacteria cell wall brings into play bactericidal action, to enterobacteriaceae lactobacteriaceaes such as escherichia coli, Proteus, Enterobacter, citric acid bacterium genus, Salmonella and Shigellas, and other gram-negative bacteria such as Pseudomonas aeruginosa, hemophilus influenza, neisseria has antibacterial action.
This paper indication clavulanic acid compounds is meant clavulanic acid and derivant thereof, clavulanic acid and derivant thereof are the wide spectrum beta-lactamase inhibitor, this medicine can with most beta-lactamase strong bonded, generate irreversible conjugate, but fungistatic effect is not obvious when being used as antibacterials separately." the clavulanic acid derivant " of indication of the present invention is the compounds that obtains after clavulanic acid and the alkali metal reaction, for example, and clavulanic acid sodium and clavulanate potassium.
Antibacterial compound drug provided by the invention comprises sulbenicillin disodium and clavulanic acid compounds, the coupling of the two has significant synergism, on germ-resistant basis, can avoid the drug resistance antibacterial to produce the decomposition of beta-lactamase, under the prerequisite that does not increase drug dose, still can obtain the good sterilization effect the sulbenicillin disodium beta-lactam nucleus.
Embodiment 1-6
Used medicine and bacterial strain are commercially available in following examples and the Comparative Examples.
Below in each embodiment and the Comparative Examples, each material is all by weight mixing.
MIC is meant that in vitro tests antibacterial compound drug can suppress the least concentration of bacterial growth in the culture medium; MIC
50(50%minimum inhibitory concentration) is 50% minimum inhibitory concentration, under same experimental conditions, and MIC
50Be worth more for a short time, illustrate that the fungistatic effect of this medicine is good more, MIC unit is ug/g.
Embodiment 1-6 and Comparative Examples 1-2 all operate and write down MIC by the experiment of measuring medicine minimum inhibitory concentration (being called for short MIC) in the common micro-organisms test
50List in the table 1.
Listed the MIC of Comparative Examples and different antimicrobial drug composition of medicine in the table 1
50The MIC of independent use sulbenicillin disodium has been shown in the Comparative Examples 1
50Value; The MIC of this antibacterial compound drug has been shown in the Comparative Examples 2 when the mass ratio of sulbenicillin disodium and clavulanic acid is 8: 1
50Value; Embodiment 1-6 illustrates, by the MIC of antibacterial compound drug provided by the invention
50Value.
Table 1 Comparative Examples 1-2 and embodiment 1-6 antibacterial compound drug MIC
50
Required MIC in the Comparative Examples 1
50Bigger, illustrate that required dose is bigger when using sulbenicillin disodium separately.
As seen from Table 1, sulbenicillin disodium in embodiment 1: clavulanic acid is 1: 1 o'clock, MIC
50Be worth higher; In Comparative Examples 2, sulbenicillin disodium: clavulanic acid is 8: 1 o'clock, the MIC of antibacterial compound drug
50Be worth higher.Thereby as seen, when the ratio of sulbenicillin disodium and clavulanic acid compounds not 2～7: in the time of in 1 the scope, can not well realize purpose of the present invention, the synergy of two kinds of medicines is not good.
In addition by table 1 as seen, sulbenicillin disodium in embodiment 4: clavulanate potassium is a sulbenicillin disodium among 4: 1 and the embodiment 2: clavulanic acid is 3: 1 o'clock, and the antibacterial compound drug consumption is all than the MIC of embodiment 3 (sulbenicillin disodium: clavulanate potassium is 3: 1)
50Height illustrates when adopting sulbenicillin disodium: 3: 1 ratio of clavulanic acid and during without clavulanate potassium, dosage is still higher, and when adopting clavulanate potassium, but ratio is not a sulbenicillin disodium: when clavulanate potassium was 3: 1, dosage was also bigger; And antibacterial effect is united in realization that could best when having only the antibacterial compound drug that adopts embodiment 3.
Should be appreciated that those skilled in the art can be under the situation that does not deviate from scope and spirit of the present invention, the specific embodiment is changed or revises, these changes or revise still within protection domain of the present invention.And the disclosure content of the publication that the application draws also all is incorporated herein with reform, with as a reference.
Claims (5)
1. antibacterial compound drug that contains sulbenicillin disodium and clavulanic acid compounds, it is characterized in that, described antibacterial compound drug is made up of sulbenicillin disodium and clavulanic acid compounds, and wherein, the weight ratio of sulbenicillin disodium and clavulanic acid compounds is 2～7: 1.
2. antibacterial compound drug according to claim 1 is characterized in that, described clavulanic acid compounds is a clavulanate potassium.
3. antibacterial compound drug according to claim 2 is characterized in that, the weight ratio of described sulbenicillin disodium and clavulanate potassium is 3: 1.
4. antibacterial compound drug according to claim 2 is characterized in that, the mass ratio of described sulbenicillin disodium and clavulanate potassium is 4: 1.
5. a lyophilized injectable powder is characterized in that, the effective ingredient of described lyophilized injectable powder is as each described antibacterial compound drug among the claim 1-4.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101144105A CN102210676A (en) | 2011-05-04 | 2011-05-04 | Antibacterial composite medicine containing sulbenicillin sodium and clavulanic acid compound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101144105A CN102210676A (en) | 2011-05-04 | 2011-05-04 | Antibacterial composite medicine containing sulbenicillin sodium and clavulanic acid compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102210676A true CN102210676A (en) | 2011-10-12 |
Family
ID=44742364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011101144105A Pending CN102210676A (en) | 2011-05-04 | 2011-05-04 | Antibacterial composite medicine containing sulbenicillin sodium and clavulanic acid compound |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102210676A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103550226A (en) * | 2013-11-12 | 2014-02-05 | 崔合芳 | Compound sulfamonomethoxine sodium injection as well as preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1732931A (en) * | 2005-08-05 | 2006-02-15 | 张舰 | Antibacterial compound drug of sulbenicillin sodium for injection |
| CN101129381A (en) * | 2006-08-25 | 2008-02-27 | 天津和美生物技术有限公司 | Antibiotic compound containing beta-lactam antibiotic and ion chelating agent |
-
2011
- 2011-05-04 CN CN2011101144105A patent/CN102210676A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1732931A (en) * | 2005-08-05 | 2006-02-15 | 张舰 | Antibacterial compound drug of sulbenicillin sodium for injection |
| CN101129381A (en) * | 2006-08-25 | 2008-02-27 | 天津和美生物技术有限公司 | Antibiotic compound containing beta-lactam antibiotic and ion chelating agent |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103550226A (en) * | 2013-11-12 | 2014-02-05 | 崔合芳 | Compound sulfamonomethoxine sodium injection as well as preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2397768C2 (en) | Intended for injection compositions for overcoming beta-lactamase-mediated resistance to antibiotics with application of beta-lactamase inhibitor | |
| JP5808860B2 (en) | Pharmaceutical composition comprising sulbactam and beta-lactamase inhibitor | |
| US20200093814A1 (en) | Combination therapy with amidine substituted beta-lactam compounds and beta-lactamase inhibitors for infections with antibiotic resistant bacterial strains | |
| Richter et al. | Innovative approaches to treat Staphylococcus aureus biofilm-related infections | |
| CN102205126A (en) | Application of combined catechin matters together with antibacterial agents | |
| JP5101521B2 (en) | Compositions and methods for sensitizing methicillin-resistant Staphylococcus aureus to oxacillin | |
| JP5276653B2 (en) | Bactericidal anti-MRSA active pharmaceutical composition comprising carbapenems | |
| TW201632177A (en) | Combination therapy effective against microorganisms including drug resistant microorganisms | |
| CN102210676A (en) | Antibacterial composite medicine containing sulbenicillin sodium and clavulanic acid compound | |
| EP1604660B1 (en) | Medicinal composition for treating infection with drug-resistant staphylococcus aureus | |
| CN102210677A (en) | Antimicrobial composition medicine containing sulbenicillin sodium and tazobactam compound | |
| CN101837126A (en) | Cephalosporin antibacterial combination and medicinal preparation thereof | |
| WO2013081284A1 (en) | Complex antibacterial composition for animals | |
| CN102462683B (en) | Antibiotic composition and preparation method and application thereof | |
| CA1068603A (en) | Preparations comprising phosphonomycin and another antibiotic | |
| CN112438989A (en) | Non-antibiotic antibacterial composition and application thereof | |
| CN1582942A (en) | Cefuroxime sodium compound preparation | |
| AU2014200107B2 (en) | Compositions and methods of treatment comprising ceftaroline | |
| CN116898862A (en) | Antibacterial composition, antibacterial drug and application | |
| Boeren et al. | Amoxicillin, stability and solubility. | |
| Beniwal et al. | Synergistically Active and Safe Fixed Dose Combination of Meropenem and Sulbactam | |
| CN101904842A (en) | Aspoxicillin antibacterial combined medicament | |
| CN103845288A (en) | Method for preparing cephalosporin compound preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20111012 |